Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px
Person › Details

Jennifer Moore (Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS))

Moore, Jennifer (Cellectis 201511 VP Communications)

 

Organisation Organisation Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
Products Product CAR-T technology (Chimeric Antigen Receptor T-Cell technology)
  Product 2 public relations / investor relations / marcom (services)
     

Cellectis S.A.. (11/30/15). "Press Release: Cellectis Announces Presentations at Upcoming Conferences". New York.

Cellectis (Alternext: ALCLS – Nasdaq: CLLS), on developing immunotherapies based on gene edited CAR-T cells (UCART), today announced presentations at the Piper Jaffray 27th Annual Healthcare Conference and the Oppenheimer 26th Annual Healthcare Conference.

• December 2, 2015 - Piper Jaffray 27th Annual Healthcare Conference - NYC
Fireside chat presentation from 1:00pm to 1:25pm ET at the New York Palace Hotel

• December 9, 2015 - Oppenheimer 26th Annual Healthcare Conference - NYC
Company presentation from 9:10am to 9:40am ET at the Westin New York Grand Central


About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it.

TALEN® is a registered trademark owned by the Cellectis Group.


For further information, please contact:

Media contacts
Jennifer Moore, VP Communications
Phone: +1 917-580-1088
email: media@cellectis.com

Caitlin Kasunich / Dixon Moretz
KCSA Strategic Communications
Phone: +1 212.896.1241 / +1 212.896.1251
email: ckasunich@kcsa.com / dmoretz@kcsa.com

Investor relations contact
Simon Harnest, VP Finance and Investor Relations
Phone: +1 646-385-9008
email: simon.harnest@cellectis.com

   
Record changed: 2019-10-08

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px


More documents for Jennifer Moore


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top